Evidence map›Paper›PMID 42193321›Full record

ReviewBiomedicines2026

Mesenchymal Stem Cells in Fungal Infections: Immunomodulation, Direct Antifungal Activity, and the Promise of the Secretome.

Maya Nehemia, Hilit Cohen, Orly Gruzman, Tal Meushar Vega Amador, Shimon B Levy, Sorina Grisaru-Granovsky, Ofra Ben Menachem-Zidon

Abstract readReview
In one paragraph

Review in Biomedicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Maya NehemiaHanan Drori Regenerative Medicine Research Laboratory, Department of Obstetrics & Gynecology, The Eisenberg R&D Authority, Shaare Zedek Medical Center, Jerusalem 9103102, Israel.
Hilit CohenHanan Drori Regenerative Medicine Research Laboratory, Department of Obstetrics & Gynecology, The Eisenberg R&D Authority, Shaare Zedek Medical Center, Jerusalem 9103102, Israel.
Orly GruzmanHanan Drori Regenerative Medicine Research Laboratory, Department of Obstetrics & Gynecology, The Eisenberg R&D Authority, Shaare Zedek Medical Center, Jerusalem 9103102, Israel.
Tal Meushar Vega AmadorHanan Drori Regenerative Medicine Research Laboratory, Department of Obstetrics & Gynecology, The Eisenberg R&D Authority, Shaare Zedek Medical Center, Jerusalem 9103102, Israel.
Shimon B LevyHanan Drori Regenerative Medicine Research Laboratory, Department of Obstetrics & Gynecology, The Eisenberg R&D Authority, Shaare Zedek Medical Center, Jerusalem 9103102, Israel.
Sorina Grisaru-GranovskyHanan Drori Regenerative Medicine Research Laboratory, Department of Obstetrics & Gynecology, The Eisenberg R&D Authority, Shaare Zedek Medical Center, Jerusalem 9103102, Israel.
Ofra Ben Menachem-ZidonHanan Drori Regenerative Medicine Research Laboratory, Department of Obstetrics & Gynecology, The Eisenberg R&D Authority, Shaare Zedek Medical Center, Jerusalem 9103102, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesenchymal stem/stromal cells (MSCs) are widely recognized as potent modulators of inflammation and immune function in bacterial and viral infections. However, their roles in fungal disease remain comparatively under-defined despite the growing clinical burden of invasive and opportunistic mycoses. This Feature Review synthesizes emerging evidence that MSCs influence antifungal outcomes through two complementary axes: (i) host-directed effects, including modulation of immune responses, particularly macrophage responses, and tissue/barrier conditioning; and (ii) fungus-directed effects (direct antifungal activity mediated by contact-dependent mechanisms and secreted antimicrobial factors). We will summarize how MSCs reshape cytokine and chemokine networks and tune innate immune effector functions, with emphasis on macrophage polarization, pattern-recognition receptor signaling, and downstream phagocytic and fungicidal pathways. In parallel, we will review data suggesting that MSCs can interact more directly with fungal pathogens through sensing, physical engagement, and secretion of antimicrobial mediators while highlighting mechanistic uncertainties and model-dependent limitations. A dedicated section will address MSC-derived secretome products (conditioned media, extracellular vesicles) as a cell-free strategy to enhance antifungal immunity. We will critically evaluate conflicting findings across studies, highlighting that outcomes depend on pathogen and host context. Clarifying these context dependencies is essential to rationally develop MSC or secretome-based interventions that are safe, reproducible, and tailored to specific fungal pathogens and patient populations.

Indexed as

direct antifungal activityimmunomodulationinvasive fungal infectionsmacrophagesmesenchymal stem cellssecretome

Identifiers

PMID42193321
PMCPMC13204446

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.